Dihydroboldenone

AR Binding and Transactivation#

DHB is structurally 5α-androst-1-en-17β-ol-3-one — a DHT skeleton with a 1(2)-double bond in the A-ring instead of DHT's saturated A-ring, or equivalently, boldenone with the 4,5-double bond shifted to 1,2 and a 5α-hydrogen in place. That single structural move makes it a potent, selective androgen receptor agonist with affinity comparable to testosterone and DHT, but with a radically different metabolic profile.

In the classic Hershberger-style orchiectomized rat bioassay, 1-T drove levator ani (skeletal muscle) and ventral prostate growth to a degree comparable to testosterone at equimolar dose — but without the estrogenic fingerprint that testosterone leaves in uterine tissue.

"1-testosterone exhibited a high AR binding affinity and androgenic activity in vivo similar to testosterone but without estrogenic effects due to lack of aromatization." — Friedel, A. et al., Toxicology Letters, 2006

Practically: AR activation in muscle upregulates myofibrillar protein synthesis, satellite cell recruitment, and local IGF-1 expression. This is the engine behind the slow, dry, high-quality tissue accrual users describe on DHB runs.

No Aromatization, No Estrogen#

The Δ1 double bond means the A-ring is not a viable substrate for aromatase (CYP19A1). DHB cannot be converted to an estrogen. Not weakly — not at all.

"As a 5α-reduced DHT derivative with a 1(2)-double bond, 1-testosterone (DHB) cannot be metabolized by aromatase into estrogen, or further reduced by 5α-reductase." — Wikipedia contributors, Wikipedia, 2024

This explains the dry, vascular, gyno-proof phenotype that defines DHB's reputation. It also explains the downside that less experienced users miss: estrogen does real work on cycle — joint lubrication, HDL maintenance, vasodilation, libido, mood, neuroprotection, and appetite. DHB provides none of it. This is why running DHB without a co-administered aromatizing testosterone base is a mistake: you end up in a functionally low-E2 state with dry joints, flat libido, and an ugly lipid panel, regardless of how well the compound itself is "working."

Not a 5α-Reductase Substrate#

DHB is already 5α-reduced. There is no further reduction pathway available to it — unlike testosterone, which is amplified 3–10× at AR in androgen-sensitive tissues (scalp, prostate, skin) via local 5α-reductase conversion to DHT.

"1-Testosterone is a synthetic anabolic steroid and a 5-alpha reduced derivative of boldenone, exhibiting significant anabolic and androgenic activity, and is not a substrate for aromatase or 5α-reductase." — DrugBank, DrugBank Online, 2024

Two practical consequences:

1. Finasteride and dutasteride do nothing against DHB at the scalp. There is no DHT conversion step to block — DHB itself is the androgen hitting the follicle. Users predisposed to androgenic alopecia who want to run DHB need topical AR antagonists (RU58841, pyrilutamide) or they need to accept the hair cost. Oral 5-ARIs are irrelevant here.
2. The muscle-to-androgenic-tissue ratio is more favorable than testosterone's in tissues that rely on 5-AR amplification, but less favorable than testosterone's in tissues that don't. DHB's often-quoted 200:100 anabolic:androgenic ratio reflects this — good AR drive in muscle, meaningful but not amplified androgenic load at skin and scalp.

Downstream Anabolic Signaling#

Once AR is activated and translocates to the nucleus, DHB drives the same transcriptional program as other potent 5α-reduced AR agonists:

"The compound binds specifically to the androgen receptor and induces strong androgenic as well as anabolic effects in the rat bioassay, paralleling observations for other 5α-reduced anabolic steroids such as DHB." — Diel, P. et al., Toxicology Letters, 2007

That program includes upregulation of myofibrillar protein synthesis, inhibition of myostatin signaling, increased erythropoietin output (hence the hematocrit creep at higher doses), and enhanced nutrient partitioning — the reason DHB has a reputation for producing visible recomp even at maintenance calories. Users cruising on test + DHB consistently report the same phenotype: leaner, drier, more vascular at the same bodyweight.

Why the "Sickness" Happens#

The less-discussed mechanism: DHB has a reproducible subset of users reporting elevated CRP, flu-like malaise, acid reflux, and creeping lethargy 2–4 weeks into a run. The exact pathway isn't characterized in the literature — no human clinical data exists on DHB inflammatory markers — but the pattern is consistent enough across community reports that it's treated as a real pharmacological effect rather than placebo or contamination.

"Most users report that DHB really turns on closer to 400mg; above 500–700mg the sides (notably PIP and creeping lethargy) can start to outpace the benefits." — MESO-Rx Community, MESO-Rx Forums, 2024

Working hypothesis in the community is a combination of strong AR-mediated inflammatory signaling in a subset of responders plus the fact that the oily 1-T ester is often carried in heavy BB/BA solvent systems that themselves produce local and systemic inflammatory signal. If CRP spikes or the malaise shows up, it usually doesn't adapt away — the correct response is to drop the compound, not push through. That's a mechanism-level reason DHB isn't a "run it and forget it" compound the way testosterone is.

Common (most users)#

• Injection site pain (PIP) — the defining nuisance of DHB. 1-Test Cyp is manageable; 1-Test Ace is notorious and has ended cycles on the first pin. Mitigate with a reputable vendor (solvent formulation matters more than potency here), thin 25g pins, warming the oil pre-injection, large muscles (glute/ventroglute over quad/delt), and diligent site rotation. If PIP is debilitating across multiple vials from the same source, switch vendors rather than toughing it out.
• Androgenic skin effects — acne on back/shoulders/chest, oily skin. Manage with a benzoyl peroxide wash, topical adapalene, and pillowcase hygiene. Flares hard above 500 mg/week.
• Libido swings — usually fine on a proper test base; erratic or crashed if you're under-dosing test, over-AI'ing, or running DHB-only. Keep test ≥150–200 mg/week and don't touch an AI unless bloods justify it.
• Aggression / short fuse — typical androgenic edge, more pronounced than test at equivalent doses. Channel it into training; lower the dose if it's affecting relationships or driving.
• Mild AST/ALT elevation — not classically hepatotoxic (not 17α-alkylated), but routine on any injectable AAS run. Don't stack with orals and daily alcohol if you want clean liver bloods.

Uncommon (dose-dependent or individual)#

• Creeping lethargy / malaise — the most-reported DHB-specific complaint. Users describe a flu-like, dragging fatigue that sets in 2–3 weeks into the cycle.

  "Most users report that DHB really turns on closer to 400mg; above 500–700mg the sides (notably PIP and creeping lethargy) can start to outpace the benefits." — MESO-Rx Community (2024)

  If it doesn't resolve within a week of dropping the dose, drop the compound — this one tends not to desensitize.

• Elevated CRP / systemic inflammation — a recurring DHB-specific signal in community bloodwork. Check CRP at week 4–6. If it's significantly above baseline with no other explanation, DHB is the likely driver and the cycle should end.

• Blood pressure creep — common above 500 mg/week. Measure daily at home. Telmisartan 40–80 mg or cialis 5 mg daily are the usual first-line adds; drop dose if BP stays >140/90 on management.

• Lipid shift — HDL suppression and LDL/ApoB elevation, in line with other non-aromatizing injectables, and without the mild E2 buffering test alone provides. Run a lipid panel mid-cycle. Citrus bergamot, a controlled-carb approach, and cardio help; ezetimibe or a low-dose statin are on the table for users running back-to-back cycles.

• Hematocrit climb — AR-driven erythropoiesis. Check CBC mid-cycle; donate blood if HCT >52%.

• Acid reflux — reported by a subset of users on DHB specifically. Famotidine 20–40 mg works; if it doesn't, back off dose.

• Scalp hair shedding — DHB is already 5α-reduced, so finasteride and dutasteride do nothing for it. Topical AR antagonists (RU58841, pyrilutamide) are the only pharmacological protection; minoxidil + microneedling supports the scalp but won't block the androgenic signal. If you're actively losing hair, this is not your compound.

Rare but serious#

• Severe persistent inflammation / sickness response — a minority of users simply don't tolerate DHB and get a sustained flu-like reaction that doesn't clear with dose reduction. Stop and don't re-challenge.
• Cardiac strain — sustained high BP, elevated hematocrit, and suppressed HDL/elevated ApoB over multi-cycle timelines raise LVH and atherosclerotic risk. Warning signs: exertional chest tightness, new arrhythmia, BP uncontrolled on two agents. Stop the cycle.
• Tendon injury — strength gains can outrun connective-tissue adaptation faster than the muscle feedback suggests. Warm thoroughly, avoid max singles early, and ramp load conservatively. Sharp localized pain in tendon (not muscle belly) is a stop signal.
• Cholestatic jaundice — rare with injectable-only AAS but possible. Yellowing of sclera, dark urine, pale stool, right-upper-quadrant pain → stop, pull a full liver panel.

Hard contraindications#

• Female use. DHB's androgenic load is comparable to testosterone and virilization (voice deepening, clitoromegaly, hirsutism) is high-probability and often irreversible. There is no viable female dose.
• Pregnancy or pregnancy potential. AAS-class teratogenicity and virilization of a female fetus.
• Untreated hypertension. DHB has no estrogenic vasoprotective offset. Control BP first or pick another compound.
• Established dyslipidemia or ApoB significantly above target. DHB will make this materially worse with no E2 buffer.
• Active cardiovascular disease, recent cardiac event, or cardiomyopathy.
• Active or suspected androgen-dependent malignancy (prostate, certain breast cancers).
• Active significant hair loss without acceptance or topical AR-antagonist plan — you cannot 5-AR-inhibit your way out of DHB.

Gender and PCT considerations#

Women: not a viable compound. The clean, estrogen-free profile that makes DHB attractive to men is precisely what makes it aggressive in women — pure AR activation at DHT-analog affinity with no estrogenic softening. Virilization risk dominates.

Men — PCT: full HPTA shutdown is expected. If you're not cruising on a TRT dose afterward, standard SERM protocol starts ~2.5–3 weeks after the final 1-Test Cyp pin (the ester's ~8-day half-life means you're still clearing it at 2 weeks out). Nolvadex 40/40/20/20 or clomid 50/50/25/25 over 4 weeks, with HCG 500 IU E3.5D during the last 2–3 weeks of the cycle if testicular atrophy is significant. Re-test total test, free test, LH, FSH, and E2 at 6–8 weeks post-PCT to confirm recovery.

Fertility: shutdown is dose- and duration-dependent. Men planning near-term conception should cruise on TRT-dose test + HCG, or avoid long DHB runs entirely.